[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR079726A1 - Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes - Google Patents

Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes

Info

Publication number
AR079726A1
AR079726A1 ARP100104922A ARP100104922A AR079726A1 AR 079726 A1 AR079726 A1 AR 079726A1 AR P100104922 A ARP100104922 A AR P100104922A AR P100104922 A ARP100104922 A AR P100104922A AR 079726 A1 AR079726 A1 AR 079726A1
Authority
AR
Argentina
Prior art keywords
copd
pulmonary disease
chronic obstructive
obstructive pulmonary
aerosol
Prior art date
Application number
ARP100104922A
Other languages
English (en)
Inventor
Francesca Usberti
Enrico Zambelli
Sauro Bonelli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079726(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR079726A1 publication Critical patent/AR079726A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04Methods of, or means for, filling the material into the containers or receptacles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003Adding propellants in fluid form to aerosol containers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00Closing containers or receptacles after filling
    • B65B7/16Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842Securing closures on containers
    • B65B7/285Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

Formulacion en aerosol que es apropiada para administrar a pacientes de enfermedad pulmonar obstructiva cronica (EPOC) por medio de un inhalador presurizado de dosis medida (pMDI), que comprende bromuro de glicopirronio en combinacion con formoterol. La formulacion comprende además un propelente de HFA, un cosolvente, y una cantidad de ácido inorgánico que es suficiente para estabilizar tanto el componente de bromuro de glicopirronio como el de formoterol. Opcionalmente la formulacion comprende además dipropionato de beclometasona. Frasco de aerosol. Método para rellenar el frasco. Conjunto de componentes. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende: (a) bromuro de glicopirronio; y (b) formoterol o una sal del mismo; disueltos en un propelente de HFA y un cosolvente, que se caracteriza porque dicha composicion contiene una cantidad de HCI 1 M en el rango entre 0,1 y 0,3 microgramos/microlitro.
ARP100104922A 2009-12-23 2010-12-22 Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes AR079726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23

Publications (1)

Publication Number Publication Date
AR079726A1 true AR079726A1 (es) 2012-02-15

Family

ID=42107420

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100104922A AR079726A1 (es) 2009-12-23 2010-12-22 Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
ARP190102199A AR115897A2 (es) 2009-12-23 2019-08-02 Composición farmacéutica para enfermedad pulmonar obstructiva crónica (epoc), frasco de aerosol que lo comprende, y método para rellenarlo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190102199A AR115897A2 (es) 2009-12-23 2019-08-02 Composición farmacéutica para enfermedad pulmonar obstructiva crónica (epoc), frasco de aerosol que lo comprende, y método para rellenarlo

Country Status (40)

Country Link
US (3) US20110150782A1 (es)
EP (1) EP2515855B3 (es)
JP (2) JP5914354B2 (es)
KR (2) KR101757951B1 (es)
CN (2) CN102665679B (es)
AR (2) AR079726A1 (es)
AU (3) AU2010334859A1 (es)
BR (1) BR112012015337B8 (es)
CA (1) CA2785321C (es)
CL (1) CL2012001705A1 (es)
CO (1) CO6541628A2 (es)
CY (2) CY1115116T1 (es)
DK (1) DK2515855T6 (es)
EA (2) EA021917B1 (es)
ES (1) ES2468840T7 (es)
FI (2) FI2515855T6 (es)
GE (1) GEP20156311B (es)
HK (2) HK1174566A1 (es)
HR (1) HRP20140582T4 (es)
HU (1) HUS1800001I1 (es)
IL (1) IL260932B (es)
LT (1) LTC2515855I2 (es)
LU (1) LUC00060I2 (es)
MA (1) MA33823B1 (es)
MX (1) MX2012006878A (es)
MY (1) MY156949A (es)
NL (1) NL300923I2 (es)
NO (1) NO2018001I1 (es)
NZ (1) NZ600790A (es)
PE (2) PE20160853A1 (es)
PL (1) PL2515855T6 (es)
PT (1) PT2515855E (es)
RS (1) RS53391B2 (es)
SG (1) SG181868A1 (es)
SI (1) SI2515855T1 (es)
TN (1) TN2012000269A1 (es)
TW (1) TWI495468B (es)
UA (1) UA113832C2 (es)
WO (1) WO2011076843A2 (es)
ZA (1) ZA201204615B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5914354B2 (ja) * 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Copd用併用療法
ES2464520T3 (es) 2009-12-23 2014-06-03 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
RU2561052C2 (ru) * 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
AU2012216890A1 (en) * 2011-02-17 2013-09-05 Cipla Limited Combination of glycopyrrolate and a beta2 -agonist
DK2765994T3 (en) 2011-10-11 2019-03-04 Chiesi Farm Spa Crystalline microparticles of a beta agonist coated with a fatty acid
KR20150096371A (ko) * 2012-10-23 2015-08-24 시플라 리미티드 티오트로피움 및 히드로플루오로알칸을 포함하는 약학적 조성물
PL3409270T3 (pl) 2013-07-11 2021-08-09 Chiesi Farmaceutici S.P.A. Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta- adrenergiczny do podawania wziewnego
LT3089735T (lt) * 2013-12-30 2018-09-10 Chiesi Farmaceutici S.P.A. Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija
MY176191A (en) * 2013-12-30 2020-07-24 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
MD3628331T2 (ro) * 2015-11-16 2021-12-31 Chiesi Farm Spa Procedeu de preparare unei formulări sub formă de pulbere uscată care cuprinde un anticolinergic, un corticosteroid și un beta-adrenergic
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
MA43782A (fr) 2016-03-31 2021-04-28 Chiesi Farm Spa Dispositif d'inhalation d'aérosol
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
ES2956521T3 (es) * 2016-09-19 2023-12-22 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de tiotropio
CN109715148A (zh) 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物
CA3037092C (en) * 2016-09-19 2022-06-21 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
CA3060020A1 (en) 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
KR20240105510A (ko) 2017-05-11 2024-07-05 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
WO2021110239A1 (en) * 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
CA3186956A1 (en) 2020-07-31 2022-02-03 Chemo Research , S.L. Combination therapy for inhalation administration
CN116419749A (zh) 2020-10-09 2023-07-11 奇斯药制品公司 用于加压定量吸入器的药物制剂
WO2023227782A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227781A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
ES2129117T3 (es) 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma Formulaciones en disolucion en forma de aerosol medicinales estabilizadas.
AU748867B2 (en) 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
NZ509489A (en) * 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
SK286394B6 (sk) 2001-03-30 2008-09-05 Jagotec Ag Lekárske aerosólové prípravky
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
GEP20063986B (en) 2002-03-01 2006-12-11 Chiesi Farma Spa Formoterol superfine formulation
PL375868A1 (en) 2002-12-16 2005-12-12 Boehringer Ingelheim Pharma Gmbh & Co.Kg Tiotropium containing hfc solution formulations
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
RU2438660C2 (ru) * 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
NZ548300A (en) 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
EP1879620A2 (en) 2005-03-30 2008-01-23 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2616505A1 (en) 2005-08-01 2007-02-08 Astrazeneca Ab Inhaler valve
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
DK1971369T3 (da) * 2005-12-21 2009-11-16 Meda Pharma Gmbh & Co Kg Kombination af R,R-glycopyrrolat, rolipram og budesonid til behandling af inflammatoriske sygdomme
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
ES2671874T3 (es) 2007-10-18 2018-06-11 Rose U, Llc Formulaciones tópicas de glicopirrolato
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
JP5914354B2 (ja) * 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Copd用併用療法
ES2464520T3 (es) * 2009-12-23 2014-06-03 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
RU2561052C2 (ru) 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
ES2467928T3 (es) * 2009-12-23 2014-06-13 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
PL3409270T3 (pl) * 2013-07-11 2021-08-09 Chiesi Farmaceutici S.P.A. Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta- adrenergiczny do podawania wziewnego
LT3089735T (lt) * 2013-12-30 2018-09-10 Chiesi Farmaceutici S.P.A. Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija
MY176191A (en) * 2013-12-30 2020-07-24 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
UA113832C2 (xx) 2017-03-27
MY156949A (en) 2016-04-15
DK2515855T3 (da) 2014-06-30
HK1174566A1 (en) 2013-06-14
US11389401B2 (en) 2022-07-19
ES2468840T3 (es) 2014-06-17
HK1197036A1 (en) 2015-01-02
CY2017047I2 (el) 2018-04-04
NL300923I1 (en) 2018-01-17
ZA201204615B (en) 2013-09-25
EA021917B1 (ru) 2015-09-30
EA027778B1 (ru) 2017-08-31
LTPA2018001I1 (lt) 2018-02-12
EA201290375A1 (ru) 2013-01-30
NL300923I2 (en) 2019-07-22
EA201590179A1 (ru) 2015-09-30
HRP20140582T1 (hr) 2014-08-01
PL2515855T6 (pl) 2023-12-18
CN102665679A (zh) 2012-09-12
CA2785321A1 (en) 2011-06-30
JP2013515696A (ja) 2013-05-09
PL2515855T3 (pl) 2014-08-29
SG181868A1 (en) 2012-07-30
MA33823B1 (fr) 2012-12-03
EP2515855B3 (en) 2023-05-03
JP5914354B2 (ja) 2016-05-11
US20110150782A1 (en) 2011-06-23
EP2515855A2 (en) 2012-10-31
LUC00060I2 (es) 2018-03-16
KR20120103653A (ko) 2012-09-19
LTC2515855I2 (lt) 2019-05-10
CN104055765A (zh) 2014-09-24
TW201129359A (en) 2011-09-01
CY2017047I1 (el) 2018-04-04
TN2012000269A1 (en) 2013-12-12
NZ600790A (en) 2014-09-26
CN104055765B (zh) 2016-11-23
CY1115116T1 (el) 2016-12-14
US20190046433A1 (en) 2019-02-14
PT2515855E (pt) 2014-06-11
CO6541628A2 (es) 2012-10-16
CN102665679B (zh) 2014-11-26
ES2468840T7 (es) 2023-11-29
IL260932B (en) 2021-04-29
FI2515855T6 (fi) 2023-06-02
KR20170040392A (ko) 2017-04-12
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
KR101757951B1 (ko) 2017-07-13
JP2016145239A (ja) 2016-08-12
PE20160853A1 (es) 2016-09-14
SI2515855T1 (sl) 2014-08-29
PE20121396A1 (es) 2012-10-24
RS53391B2 (sr) 2023-09-29
BR112012015337B1 (pt) 2021-05-04
AU2016234895B2 (en) 2018-02-01
TWI495468B (zh) 2015-08-11
RS53391B (en) 2014-10-31
HUS1800001I1 (hu) 2018-02-28
LUC00060I1 (es) 2018-01-18
AU2018202998A1 (en) 2018-05-17
DK2515855T6 (da) 2023-06-06
AU2016234895A1 (en) 2016-10-13
WO2011076843A3 (en) 2011-12-01
NO2018001I2 (no) 2018-01-10
JP6283388B2 (ja) 2018-02-21
US10159645B2 (en) 2018-12-25
NO2018001I1 (no) 2018-01-10
HRP20140582T4 (hr) 2023-06-09
EP2515855B1 (en) 2014-04-02
BR112012015337B8 (pt) 2021-05-25
GEP20156311B (en) 2015-07-10
US20150328144A1 (en) 2015-11-19
CL2012001705A1 (es) 2012-09-28
AU2010334859A1 (en) 2012-07-12
WO2011076843A2 (en) 2011-06-30
FIC20170064I1 (fi) 2017-12-29
CA2785321C (en) 2018-08-21
MX2012006878A (es) 2012-07-04

Similar Documents

Publication Publication Date Title
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
AR038641A1 (es) Formulacion superfina de formoterol
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
AR101593A2 (es) Formulación superfina de formoterol
WO2011076841A3 (en) Combination therapy for copd
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
PE20091672A1 (es) Nueva dosificacion y formulacion
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
UA106098C2 (uk) Аерозольна композиція для хозл
WO2012040228A3 (en) Aerosol composition for administering drugs
AR089302A1 (es) Un medicamento inhalable
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
BR112015026053A8 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de um componente propelente, e, método para fabricação de uma composição farmacêutica
AR040450A1 (es) Formulacion superfina de salmeterol
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
BR112014003907A2 (pt) método para preparar inalador pulverizado de dose medida para tratar doença respiratória
TH127043A (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero
TH127043B (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd
AR103475A1 (es) Un medicamento inhalable

Legal Events

Date Code Title Description
FC Refusal